{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:46:42Z","timestamp":1792097202832,"version":"4.4.0"},"reference-count":0,"publisher":"American Society of Hematology","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Children with Down syndrome (DS) have an increased risk of acute lymphoblastic leukemia (ALL). Although recent reports describe some improvement, survival in DS-ALL remains inferior to that of non-DS-ALL. This study evaluated the prognosis, relapse patterns, and treatment-related toxicities of DS-ALL in the Japan Children's Cancer Group ALL-B12 trial, a nationwide prospective study using risk-adapted therapy. A total of 1,804 patients, including 44 DS-ALL, were analyzed. Risk classification used standardized criteria. The 5-year event-free survival and overall survival in DS-ALL were 70.5% and 81.8%, respectively, lower than 85.6% and 94.6% in non-DS-ALL (P &amp;lt; 0.001). Survival differences were most pronounced in standard-risk patients. DS-ALL showed fewer favorable genetics and relapse patterns dominated by isolated bone marrow events, with no CNS relapse. CRLF2 rearrangement was assessable in 43 of 44 DS-ALL cases; 15 of 43 (34.9%) were positive. In an exploratory analysis excluding canonical favorable or unfavorable subtypes (n = 36), the 5-year EFS in DS-ALL with and without CRLF2 rearrangement were 57.1% and 81.8%, respectively (P = 0.300), and the corresponding 5-year OS were 78.6% and 86.4%, respectively (P = 0.331). Treatment-related toxicities were more frequent in DS-ALL, including mucositis (27.3% vs. 7.1%), hyperglycemia (25.0% vs. 6.9%), and pulmonary infections (20.5% vs. 7.4%). Among DS-ALL patients with TP2 MRD \u2265 10-4 (n = 3), all relapsed and died within three years. No treatment-related death was recorded after induction, but one death of undetermined cause occurred. These findings highlight the continuing need to optimize DS-ALL therapy to reduce relapse and toxicity. UMIN CT Registry (UMIN000009339) and JCT (jRCTs041180101).<\/jats:p>","DOI":"10.1182\/bloodadvances.2026021259","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:10:47Z","timestamp":1792095047000},"update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Prognosis and treatment-related toxicities in Down syndrome acute lymphoblastic leukemia in JCCG ALL-B12"],"prefix":"10.1182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5313-7161","authenticated-orcid":false,"given":"Shunsuke","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Iijima-Yamashita","sequence":"additional","affiliation":[{"name":"National Hospital Organization Nagoya Medical Center, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sanada","sequence":"additional","affiliation":[{"name":"National Hospital Organization Nagoya Medical Center, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Imamura","sequence":"additional","affiliation":[{"name":"Kyoto Prefectural University of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kada","sequence":"additional","affiliation":[{"name":"Center for Translational Research Center, Fujita Health University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3723-8445","authenticated-orcid":false,"given":"Akiko M.","family":"Saito","sequence":"additional","affiliation":[{"name":"NHO Nagoya Medical Center, Nagoya-shi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Koh","sequence":"additional","affiliation":[{"name":"Saitama Children's Medical Center, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4412-6441","authenticated-orcid":false,"given":"Yasuhiro","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Kagoshima University Hospital, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,15]]},"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2026021259\/2595541\/bloodadvances.2026021259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2026021259\/2595541\/bloodadvances.2026021259.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:10:48Z","timestamp":1792095048000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/doi\/10.1182\/bloodadvances.2026021259\/571582\/Prognosis-and-treatment-related-toxicities-in-Down"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026021259","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"article-number":"bloodadvances.2026021259"}}